

Dietary Iron Intake and Mental and Behavioral Disorders Due to Use of Tobacco: A Cross-Sectional and Longitudinal Study Based on the UK Biobank

Xueting Qi¹, Ronghui Zhang¹, Hailong Zhu¹, Jia Luo¹, Qiuge Zhang¹,
Weijing Wang¹, Tong Wang¹, Dongfeng Zhang¹.

¹: Department of Epidemiology and Health Statistics, the School of
Public Health of Qingdao University, 308 Ningxia Road, Qingdao,
Shandong 266071, People's Republic of China.

Corresponding author:

Dongfeng Zhang, Department of Epidemiology and Health Statistics, the
School of Public Health of Qingdao University, 308 Ningxia Road,
Qingdao, Shandong 266071, People's Republic of China.

Tel.: +8653282991712, Fax: +8653283801449, E-mail:
zhangdf1961@126.com

Tong Wang, Department of Epidemiology and Health Statistics, the
School of Public Health of Qingdao University, 308 Ningxia Road,
Qingdao, Shandong 266071, People's Republic of China.

Tel.: +8653282991712, Fax: +8653283801449, E-mail:
wangtong0106@126.com

26 ABSTRACT

27 **Introduction:** Over 1 billion smokers worldwide, one-third of whom
28 have mental and behavioral disorders, exist. However, factors influencing
29 mental and behavioral disorders due to use of tobacco remain unexplored.
30 We aim to investigate the relationship between dietary iron intake and
31 mental and behavioral disorders due to use of tobacco.

32 **Methods:** Using large population cohort data from the UK Biobank, we
33 employed logistic and Cox regression to explore the cross-sectional and
34 longitudinal associations between dietary iron intake and mental and
35 behavioral disorders due to use of tobacco. Additionally, we assessed the
36 nonlinear relationship between dietary iron intake and mental and
37 behavioral disorders due to use of tobacco using restricted cubic spline
38 plots.

39 **Results:** The cross-sectional analysis included 50,991 participants. The
40 logistic regression results indicated that dietary iron intake was negatively
41 associated with mental and behavioral disorders due to use of tobacco. A
42 total of 50,921 participants were included in the cohort study. The Cox
43 regression results supported the protective effect of increased dietary iron
44 intake against mental and behavioral disorders due to use of tobacco. The
45 stratified and sensitivity analysis results were consistent with the main
46 results. The restricted cubic spline plots showed a nonlinear relationship
47 between dietary iron intake and mental and behavioral disorders due to
48 use of tobacco. The risk reduction rate initially accelerated and then
49 slowed in the total sample, the two age, and the male groups. In contrast,
50 it declined rapidly at first and then leveled off in the female group.

51 **Conclusion:** This study found that dietary iron intake has a protective
52 effect against mental and behavioral disorders due to use of tobacco,
53 revealing a nonlinear association between the two. These findings offer

54 valuable insights for the prevention and treatment of mental and
55 behavioral disorders due to use of tobacco in the future.

56

57 **Keywords:** Dietary iron, Tobacco, Mental and behavioral disorders, UK
58 Biobank.

59

60 **What is already known on this topic**

61 Existing research primarily focuses on tobacco as a risk factor for
62 physical diseases. In contrast, the factors influencing mental and
63 behavioral disorders due to use of tobacco have not been adequately
64 explored. Furthermore, findings regarding the relationship between
65 dietary iron intake and mental health in the general population are
66 inconsistent, highlighting the need for this study to clarify the potential
67 association between dietary iron intake and mental and behavioral
68 disorders due to use of tobacco among smokers.

69 **What this study adds**

70 In this combined cross-sectional and longitudinal study, we assessed the
71 association between dietary iron intake and mental and behavioral
72 disorders due to use of tobacco using data from UK Biobank. We found
73 that high dietary iron intake was protective against mental and behavioral
74 disorders due to use of tobacco. In the fully adjusted model, the OR (95%
75 CI) and HR (95% CI) for the highest intake group compared to the lowest
76 intake group were 0.41 (0.18 - 0.98) and 0.50 (0.43 - 0.58), respectively.
77 In addition, we found a similar L-shaped nonlinear association between
78 dietary iron intake and mental and behavioral disorders due to use of
79 tobacco utilizing restricted cubic spline plots.

80 **How this study might affect research, practice or policy**

81 Our study provides evidence of a negative association between dietary
82 iron intake and mental and behavioral disorders due to use of tobacco.
83 For groups that find it difficult to quit smoking, increasing iron intake to
84 an appropriate level may alleviate the discomfort associated with mental
85 and behavioral disorders due to use of tobacco. National mental health is
86 crucial for every country, and this becomes especially important in a
87 modern context where mental stress is increasingly recognized.

1 INTRODUCTION

The tobacco epidemic is one of the greatest public health threats that the world has ever faced[1]. The clear realization that tobacco is a risk factor for a variety of diseases, including lung cancer, attracts the vast majority of attention[2-6]. However, mental and behavioral disorders due to use of tobacco have rarely been studied. Mental and behavioral disorders due to the use of tobacco refer to dependence syndrome, harmful use, withdrawal state, and acute intoxication, etc.[7]. These disorders are characterized by strong urges to smoke, inability to control cessation, and withdrawal symptoms such as frustration, anxiety, and irritability[8]. There were more than 1 billion smokers worldwide in 2019, which is still increasing today[9]. According to the American Lung Association, 35% of smokers have behavioral health disorders[10]. Among those hospitalized for schizophrenia, depression, or bipolar disorder, approximately half of the deaths are due to smoking-related causes[11]. Therefore, it is critical to identify and manage the influence factors for mental and behavioral disorders due to use of tobacco.

Tobacco use causes nicotine to bind to and activate acetylcholine receptors in the body, which results in dopamine release[12]. However, repeated exposure to nicotine leads to desensitization of these receptors, resulting in decreased dopamine release and contributing to mental and behavioral disorders[13]. Iron, an essential nutrient, is closely related to physical and mental health[14-18]. One of the physiological roles of iron is to promote dopaminergic signaling by enhancing the expression of the D2 neurotransmitter, increasing dopamine release[19]. Based on this, we hypothesize that there is an association between dietary iron intake with mental and behavioral disorders due to use of tobacco.

Many studies have currently reported connections between iron and

117 mental and behavioral disorders with inconsistent conclusions. For
 118 example, one study provided evidence of a negative correlation between
 119 circulating iron levels and depression and anxiety across different age and
 120 gender groups[20]. Similarly, another study found that dietary iron intake
 121 had a negative association with the risk of depression[21]. In contrast,
 122 one study indicated that excessive iron increased the risk of depression
 123 and anxiety[22]. Despite numerous investigations in the general
 124 population, there has been no research on the relationship between dietary
 125 iron intake and mental and behavioral disorders due to use of tobacco
 126 among smokers[23, 24].

127 Therefore, we conducted a cross-sectional and cohort study using data
 128 from the UK Biobank (UKB) to explore both the cross-sectional and
 129 longitudinal associations between dietary iron intake and mental and
 130 behavioral disorders due to use of tobacco. Additionally, we employed
 131 restricted cubic spline curves to clarify the dose-response relationship
 132 between dietary iron intake and mental and behavioral disorders due to
 133 use of tobacco.

134

135 2 METHODS

136 2.1 Study participant and design

137 The UKB is a large prospective population-based study that assessed
 138 approximately 500,000 participants at 22 assessment centers between
 139 2006 and 2010, including detailed health data, genomic information, and
 140 lifestyle data for each individual. These assessment centers covered
 141 various settings in the UK, ensuring a broad distribution of all exposures
 142 to detect reliable generalized associations between baseline
 143 characteristics and health outcomes. Additionally, the UKB was
 144 combined with UK national datasets for longitudinal follow-up of
 145 individual information. The study has received ethical approval from the
 146 North West Multi-Centre Research Ethics Committee in the UK
 147 (reference number: 11/NW/0382, 16/NW10274, 21/NW/0157), and all
 148 participants provided written informed consent. The specific filtering
 149 process is illustrated in Figure 1.

150




Figure 1 Flow diagram of study participant selection.

2.2 Exposure

Between April 2009 and September 2010, participants' overall dietary intake information for the past 24 hours was collected at assessment centers in the UK using an online questionnaire called Oxford WebQ. This 24-hour dietary assessment tool is specifically designed for large prospective studies. It asks participants to provide dietary information using specified standard portion sizes within given food categories[25]. Statistical data indicated that Oxford WebQ correlated with most nutrients equal to or greater than interviewer-administered dietary information[26]. In the Oxford WebQ, the intake of food nutrients, including iron, was automatically calculated by multiplying the consumed portions by the predetermined quantity of each food and its corresponding nutrient content[27].

168 **2.3 Outcome**

169 The outcome of this study was mental and behavioral disorders due to use
 170 of tobacco, identified using the International Classification of Diseases,
 171 10th edition (ICD-10) codes. The outcome code was F17 in ICD-10,
 172 including F17.0 (acute intoxication), F17.1 (harmful use), F17.2
 173 (dependence syndrome), F17.3 (withdrawal state), F17.4 (withdrawal
 174 state with delirium), F17.7 (residual and late-onset psychotic disorder),
 175 F17.9 (unspecified mental and behavioral disorder), with more details
 176 available on the UKB website (<https://www.ukbiobank.ac.uk/>). New
 177 cases and the onset time were determined based on the first diagnosis
 178 recorded in the hospital inpatient database during the follow-up period.
 179 The date of death was obtained from the UK National Death Register.
 180 The follow-up period ended on the date of onset, date of death, date of
 181 loss to follow-up, or the date of observation termination (December 31,
 182 2022), with the earliest occurrence taking precedence.

183

184 **2.4 Covariates**

185 Based on previous research, the following factors were included as
 186 covariates in the study: age, sex (male, female), ethnicity (White, other),
 187 body mass index (BMI), physical activity level (low, moderate, high),
 188 energy intake, Townsend Deprivation Index (TDI), education
 189 qualifications ("college or university degree and other professional
 190 qualifications" were categorized as "College and above," while the
 191 remaining qualifications were categorized as "Below College"), alcohol
 192 consumption (never, previous, current), employment status ("employed in
 193 paid employment or self-employed" was categorized as "Full-time work",
 194 while the remaining categories were classified as "Non-full-time work"),
 195 hypertension (yes, no), stroke (yes, no), and diabetes (yes, no)[28-36].

Physical activity levels were classified based on Metabolic Equivalent Task (MET) score data derived from the International Physical Activity Questionnaire (IPAQ) guidelines[37].

2.5 Statistical analysis

In descriptive studies, continuous variables were described by mean and standard deviation (SD) and categorical variables by numbers (N) and percentages (%). Dietary iron intake was divided into four quartiles (Q1: <25th percentile, Q2: 25th to 50th percentile, Q3: 50th to 75th percentile, and Q4: >75th percentile), with the lowest quartile as the reference group.

In cross-sectional studies, logistic regression models were employed to estimate the association between dietary iron intake and mental and behavioral disorders due to use of tobacco. Results were reported as odds ratios (OR) and 95% confidence intervals (CI).

In the cohort study, the Cox proportional hazards model was used to assess the longitudinal associations between dietary iron intake and mental and behavioral disorders due to use of tobacco. The time scale was the follow-up duration from baseline to the occurrence of outcomes, death, loss to follow-up, or the end of observation (whichever occurred first, measured in days). Results were reported as hazard ratios (HR) with 95%CI.

A total of four models were fitted in this study. Model 1 included no covariates. Model 2 adjusted for age, sex, ethnicity, education qualifications, employment status, and TDI. Model 3 further adjusted for BMI, physical activity level, energy intake, and alcohol consumption. Model 4 was additionally adjusted for hypertension, diabetes, and stroke.

To further evaluate the robustness of the cohort analysis results, we conducted the following sensitivity analyses: (1) Considering the chronic

224 and long-term nature of the effects of dietary factors on mental and
 225 behavioral disorders in the cohort analysis, we excluded participants
 226 diagnosed with mental and behavioral disorders due to use of tobacco in
 227 the 2 years prior to follow-up. (2) Given the strong association between
 228 sleep and mental health, we adjusted for sleep duration[38]. A sleep
 229 duration of 7-8 hours was classified as normal sleep, while other
 230 durations were classified as abnormal sleep. (3) Participants with extreme
 231 iron intake were excluded (intake < first percentile and > ninety-ninth
 232 percentile). (4) Participants with a history of hypertension, diabetes, or
 233 stroke at baseline were excluded. Moreover, stratified analyses were
 234 performed according to sex, age, and BMI, while the interaction was
 235 examined using a Wald test. Age was divided into two groups: ≤ 60 years
 236 and > 60 years, and BMI was divided into four groups: $< 18.5 \text{ kg/m}^2$, \geq
 237 18.5 kg/m^2 & $< 25 \text{ kg/m}^2$, $\geq 25 \text{ kg/m}^2$ & $< 30 \text{ kg/m}^2$, $\geq 30 \text{ kg/m}^2$.

238 Additionally, we treated dietary iron intake as a continuous variable
 239 and employed restricted cubic splines to examine the dose-response
 240 relationship between dietary iron intake and mental and behavioral
 241 disorders due to use of tobacco. Considering the varying iron
 242 requirements based on age and sex, we investigated the dose-response
 243 relationships separately for different gender and age groups.

244 Statistical analyses were performed in R version 4.2.3, and a P -value <
 245 0.05 for a two-sided test was considered statistically significant.

246

247 **3 RESULTS**

248 **3.1 Participant baseline characteristics**

249 The cross-sectional analysis included 50,991 participants and a total of
 250 50,921 participants were included in the cohort study. The baseline
 251 characteristics of study participants grouped by dietary iron intake are
 252 shown in Table 1. Compared to participants with the lowest dietary iron
 253 intake, those with the highest intake were more likely to be male,
 254 non-full-time workers, and individuals with diabetes. They tended to have
 255 lower BMI and TDI while exhibiting higher levels of physical activity,
 256 energy intake, education qualifications, and alcohol consumption.

257

258

Table 1 Baseline characteristics of the quartile of dietary iron intake.

Characteristic	Dietary iron intake (mg/day)				P for groups
	Q1 ≤ 9.35	Q2 > 9.35 & ≤ 12.04	Q3 > 12.04 & ≤ 15.10	Q4 > 15.10	
Age (mean (SD))	55.79 (8.24)	56.55 (8.05)	56.70 (8.10)	56.58 (8.23)	<0.001
Sex (N (%))					<0.001
Female	8183 (64.28%)	7468 (58.66%)	6712 (52.73%)	5223 (41.03%)	
Male	4548 (35.72%)	5262 (41.34%)	6018 (47.27%)	7507 (58.97%)	
Ethnicity (N (%))					<0.001
White	11527 (90.54%)	12089 (94.96%)	12182 (95.7%)	12125 (95.25%)	
Other	1204 (9.46%)	641 (5.04%)	548 (4.3%)	605 (4.75%)	
BMI (mean (SD))	27.50 (5.00)	27.03 (4.64)	27.03 (4.61)	27.17 (4.66)	<0.001
Physical activity level (N (%))					<0.001
Low	2550 (20.03%)	2229 (17.51%)	2052 (16.12%)	1915 (15.04%)	
Moderate	5301 (41.64%)	5360 (42.11%)	5352 (42.04%)	5021 (39.44%)	
High	4880 (38.33%)	5141 (40.38%)	5326 (41.84%)	5794 (45.51%)	
Energy intake (mean (SD))	6085.99 (1763.05)	7872.04 (1729.02)	9136.24 (1931.98)	11640.68 (3042.33)	<0.001
TDI (mean (SD))	-1.04 (2.94)	-1.44 (2.74)	-1.47 (2.74)	-1.34 (2.79)	<0.001
Education qualifications (N (%))					<0.001
College and above	4980 (39.12%)	5672 (44.56%)	5917 (46.48%)	6203 (48.73%)	
Below College	7751 (60.88%)	7058 (55.44%)	6813 (53.52%)	6527 (51.27%)	
Alcohol consumption (N (%))					<0.001
Never	658 (5.17%)	438 (3.44%)	400 (3.14%)	330 (2.59%)	
Previous	594 (4.67%)	424 (3.33%)	385 (3.02%)	393 (3.09%)	
Current	11479 (90.17%)	11868 (93.23%)	11945 (93.83%)	12007 (94.32%)	
Employment status (N (%))					<0.001

Characteristic	Dietary iron intake (mg/day)				<i>P</i> for groups
	Q1 ≤ 9.35	Q2 > 9.35 & ≤ 12.04	Q3 > 12.04 & ≤ 15.10	Q4 > 15.10	
Full-time work	7610 (59.78%)	7445 (58.48%)	7268 (57.09%)	7232 (56.81%)	0.083
Non-full-time work	5121 (40.22%)	5285 (41.52%)	5462 (42.91%)	5498 (43.19%)	
Hypertension (N (%))					0.685
Yes	3662 (28.76%)	3621 (28.44%)	3628 (28.5%)	3784 (29.73%)	
No	9069 (71.24%)	9109 (71.56%)	9102 (71.5%)	8946 (70.27%)	0.040
Stroke (N (%))					
Yes	266 (2.09%)	252 (1.98%)	256 (2.01%)	278 (2.18%)	0.040
No	12465 (97.91%)	12478 (98.02%)	12474 (97.99%)	12452 (97.82%)	
Diabetes (N (%))					0.040
Yes	685 (5.38%)	641 (5.04%)	604 (4.74%)	692 (5.44%)	
No	12046 (94.62%)	12089 (94.96%)	12126 (95.26%)	12038 (94.56%)	

Note: N: numbers, SD: standard deviation, BMI: body mass index, TDI: Townsend deprivation index.

3.2 Cross-sectional analysis

At baseline, there were 70 patients with mental and behavioral disorders due to use of tobacco. The results of the cross-sectional analysis are displayed in Table 2. According to the results, all four models showed that dietary iron intake was negatively associated with mental and behavioral disorders due to use of tobacco. The model 4 (adjusted for age, sex, ethnicity, BMI, physical activity level, energy intake, TDI, education qualifications, alcohol consumption, employment status, hypertension, stroke, and diabetes) indicated that compared to the Q1 group, OR (95%CI) for the Q2, Q3, and Q4 groups were 0.42 (0.21 - 0.83), 0.26 (0.12 - 0.60), and 0.41 (0.18 - 0.98), respectively.

Table 2 Association between dietary iron intake and mental and behavioral disorders due to use of tobacco in the cross-sectional study.

Dietary iron intake	Model1		Model2		Model3		Model4	
	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value
Q1	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.
Q2	0.42 (0.22 - 0.80)	0.008	0.44 (0.23 - 0.85)	0.014	0.42 (0.21 - 0.83)	0.013	0.42 (0.21 - 0.83)	0.012
Q3	0.29 (0.14 - 0.61)	0.001	0.29 (0.14 - 0.62)	0.001	0.27 (0.12 - 0.61)	0.002	0.26 (0.12 - 0.60)	0.001
Q4	0.55 (0.30 - 0.99)	0.046	0.51 (0.28 - 0.94)	0.030	0.43 (0.18 - 1.01)	0.053	0.41 (0.18 - 0.98)	0.044

Note: Model 1 was not adjusted for covariates. Model 2 adjusted for age, sex, ethnicity, education qualifications, employment status, and TDI. Model 3 further adjusted for BMI, physical activity level, energy intake, and alcohol consumption. Model 4 further adjusted for hypertension, diabetes, and stroke.

3.3 Cohort analysis

During a median follow-up of 6.84 years, 1,404 new cases of mental and behavioral disorders due to use of tobacco were identified. The association between dietary iron intake and the risk of mental and behavioral disorders due to use of tobacco is presented in Table 3. The Cox proportional hazards model did not violate the proportional hazards assumption. According to the results, Model 4 indicated that the risk of mental and behavioral disorders due to use of tobacco was reduced in Q2 (HR: 0.60, 95%CI: 0.53 - 0.68, P : <0.001), Q3 (HR: 0.59, 95%CI: 0.52 - 0.67, P : <0.001), and Q4 (HR: 0.50, 95%CI: 0.43 - 0.58, P : <0.001) groups compared to the Q1 group, and this association was observed in Models 1, 2, and 3.

Table 3 Longitudinal association between dietary iron intake and mental and behavioral disorders due to use of tobacco.

Dietary iron intake	Model1		Model2		Model3		Model4	
	HR (95%CI)	<i>P</i> -value	HR (95%CI)	<i>P</i> -value	HR (95%CI)	<i>P</i> -value	HR (95%CI)	<i>P</i> -value
Q1	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.	1.00 (Ref.)	Ref.
Q2	0.60 (0.53 - 0.68)	<0.001	0.67 (0.59 - 0.75)	<0.001	0.60 (0.53 - 0.68)	<0.001	0.60 (0.53 - 0.68)	<0.001
Q3	0.59 (0.52 - 0.67)	<0.001	0.70 (0.63 - 0.79)	<0.001	0.59 (0.52 - 0.67)	<0.001	0.59 (0.52 - 0.67)	<0.001
Q4	0.50 (0.43 - 0.59)	<0.001	0.71 (0.63 - 0.79)	<0.001	0.50 (0.43 - 0.59)	<0.001	0.50 (0.43 - 0.58)	<0.001

Note: Model 1 was not adjusted for covariates. Model 2 adjusted for age, sex, ethnicity, education qualifications, employment status, and TDI. Model 3 further adjusted for BMI, physical activity level, energy intake, and alcohol consumption. Model 4 further adjusted for hypertension, diabetes, and stroke.

3.4 Stratified analysis

The stratified analysis results are shown in Supplementary Table 1. When stratified by age, both age groups resulted in a reduced risk of mental and behavioral disorders due to use of tobacco as dietary iron intake increased. In the ≤ 60 age group, the HR (95% CI) was 0.58 (0.50 - 0.67), 0.57 (0.49 - 0.67), and 0.45 (0.37 - 0.55) for the Q2, Q3, and Q4 groups, respectively, compared to the Q1 group. In the > 60 age group, HR (95% CI) was 0.62 (0.51 - 0.76), 0.60 (0.49 - 0.75), and 0.56 (0.44 - 0.73) in Q2, Q3, and Q4 groups respectively compared to the Q1 group.

When analyzed by sex, the male and female results were consistent with the main analysis findings. In females, the HR (95% CI) for the Q2, Q3, and Q4 groups compared to the Q1 group were 0.63 (0.53 - 0.75), 0.60 (0.50 - 0.73), and 0.59 (0.47 - 0.75), respectively. In males, the HR (95% CI) for the Q2, Q3, and Q4 groups compared to the Q1 group were 0.58 (0.49 - 0.68), 0.58 (0.49 - 0.69), and 0.45 (0.37 - 0.55), respectively.

When stratifying by BMI, only the group with BMI < 18.5 kg/m² did not yield statistically significant results. This might have been due to the small sample size of this subgroup (N = 263). In the group with BMI ≥ 18.5 kg/m² & < 25 kg/m², the HR (95% CI) for the Q2, Q3, and Q4 groups compared to the Q1 group were 0.50 (0.40 - 0.62), 0.47 (0.38 - 0.59), and 0.37 (0.29 - 0.49), respectively. In the group with BMI ≥ 25 kg/m² & < 30 kg/m², the HR (95% CI) for the Q2, Q3, and Q4 groups were 0.62 (0.51 - 0.74), 0.61 (0.50 - 0.74), and 0.50 (0.40 - 0.64), respectively. In the group with BMI ≥ 30 kg/m², the HR (95% CI) for the Q2, Q3, and Q4 groups were 0.72 (0.57 - 0.90), 0.76 (0.59 - 0.97), and 0.68 (0.51 - 0.92), respectively.

Furthermore, no statistically significant differences were observed between the subgroups.

3.4 Sensitivity analysis

After excluding individuals diagnosed within the first two years of follow-up, the association between higher dietary iron intake and a lower risk of mental and behavioral disorders due to use of tobacco remained unchanged (Supplementary Table 2). In Model 4, groups Q2 (HR: 0.60, 95%CI: 0.53-0.68, $P < 0.001$), Q3 (HR: 0.59, 95%CI: 0.52-0.67, $P < 0.001$) and Q4 (HR: 0.52, 95%CI: 0.44-0.61, $P < 0.001$) had reduced risk compared to group Q1.

Adjusting for sleep duration did not significantly change the main analysis results (Supplementary Table 3). In Model 4, compared to group Q1, the risk was reduced in Q2 (HR: 0.61, 95%CI: 0.54 - 0.68, $P < 0.001$), Q3 (HR: 0.60, 95%CI: 0.53 - 0.67, $P < 0.001$), and Q4 (HR: 0.51, 95%CI: 0.43 - 0.59, $P < 0.001$) groups.

Additionally, after excluding participants with extreme dietary iron intake, the findings remained consistent with the main analysis (Supplementary Table 4). In Model 4, groups Q2 (HR: 0.62, 95%CI: 0.55-0.70, $P < 0.001$), Q3 (HR: 0.60, 95%CI: 0.52-0.68, $P < 0.001$) and Q4 (HR: 0.49, 95%CI: 0.42-0.57, $P < 0.001$) had reduced risk compared to group Q1.

Finally, excluding participants with hypertension, stroke, and diabetes did not alter the association (Supplementary Table 5). In Model 3, compared to group Q1, the risk was reduced in Q2 (HR: 0.59, 95%CI: 0.51 - 0.68, $P < 0.001$), Q3 (HR: 0.56, 95%CI: 0.48 - 0.65, $P < 0.001$), and Q4 (HR: 0.47, 95%CI: 0.39 - 0.56, $P < 0.001$) groups.

These sensitivity analysis results confirmed the robustness of the study findings.

3.6 Restricted cubic spline

The results of the restricted cubic spline analysis indicated a similar L-shaped nonlinear relationship between dietary iron intake and mental and behavioral disorders due to use of tobacco. As dietary iron intake increased, the risk of these disorders decreased. A significant risk reduction was observed when intake was approximately between 0 to 12 mg/day. However, the risk reduction rate slowed when the intake exceeded about 12 mg/day (Figure 2).

When stratified by age, the trend in risk changes was similar to what was previously described. The inflection point for the ≤ 60 years and the >60 years groups was around 12 mg/day (Supplementary Figures 1a and 1b).

When stratified by sex, the trend in risk change for males followed a similar pattern to that previously described, with an inflection point at approximately 13 mg/day (Supplementary Figure 1c). In females, however, an L-shape was observed between dietary iron intake and mental and behavioral disorders due to use of tobacco. A significant risk reduction occurred when intake was around 0 to 11 mg/day. When intake exceeded approximately 11 mg/day, the risk reduction rate began to plateau (Supplementary Figure 1d).




Figure 2 Restricted cubic spline plots of dietary iron intake and mental and behavioral disorders due to use of tobacco.

4 DISCUSSION

In this study, we conducted logistic regression and Cox regression analyses based on the UKB population sample, finding that higher dietary iron intake was associated with a lower risk of mental and behavioral disorders due to use of tobacco. Stratified analysis results supported the protective effect of dietary iron intake on mental and behavioral disorders due to use of tobacco. The sensitivity analysis results were consistent with the main analysis results. Additionally, the restricted cubic spline analysis revealed a nonlinear relationship between dietary iron intake and mental and behavioral disorders due to use of tobacco. In the overall population, both age groups and the male group, the risk of increasing dietary iron intake initially decreased rapidly before slowing down. For females, the trend in risk change was characterized by a rapid initial decline followed by stabilization.

In this study, we observed that higher dietary iron intake was associated with a reduced risk of mental and behavioral disorders due to use of tobacco. Although there is no epidemiological evidence linking dietary iron intake to mental and behavioral disorders due to use of tobacco, a large number of previous studies have explored the relationship between iron and mental and behavioral disorders. It is evident that mental and behavioral disorders due to use of tobacco are a subset of this broader category. For example, one clinical study found that iron deficiency significantly increased the risk of both psychiatric comorbidity and individual psychiatric disorders[39]. Results from another study supported the association of iron deficiency with depressive symptoms[40]. A clinical study revealed that low iron levels were associated with a significantly higher risk of developing mental disorders[41]. In addition, animal experiments found that rats fed an

iron-deficient diet exhibited more anxiety-like behaviors than control rats, supporting the findings of observational studies in humans[42]. These findings supported our results to some extent.

Mental and behavioral disorders due to use of tobacco are primarily driven by nicotine dependence[43]. Nicotine is a sympathomimetic stimulant that binds to nicotinic acetylcholine receptors in the brain[44, 45]. It releases dopamine and other neurotransmitters, such as norepinephrine, which induce feelings of pleasure[46]. Repeated exposure to nicotine increases the number of nicotinic acetylcholine receptors, altering the brain's reward system and raising the threshold for pleasure[46, 47]. When these receptors are not bound to nicotine, individuals may experience mental and behavioral disorders such as inattention, restlessness, and irritability[43]. Iron plays a crucial role in the synthesis and release of dopamine. On the one hand, iron can increase dopamine release by promoting the work of dopamine transporter proteins[48]. On the other hand, iron can enhance dopaminergic signaling by increasing the affinity and expression of D2 neurotransmitters[49]. In addition, iron is an essential cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis[50]. Sufficient iron levels can enhance tyrosine hydroxylase activity, thereby increasing dopamine production and alleviating mental disorders[51].

This study had several strengths. Firstly, it represented the first exploration of the association between dietary iron intake and mental and behavioral disorders due to use of tobacco. In addition, we explored the L-shaped and similar L-shape association between dietary iron intake and mental and behavioral disorders due to use of tobacco using restricted cubic spline plots. Secondly, we combined both cross-sectional and longitudinal studies, verifying the results from the cross-sectional

analysis with cohort studies to ensure reliability. Thirdly, we utilized a large population cohort from the UKB, enhancing the representativeness of our sample. Finally, we comprehensively included various covariates and conducted multiple sensitivity and stratified analyses to assess the robustness of our findings.

We acknowledged several limitations. Firstly, dietary iron intake information was obtained from participants' online questionnaires, which might introduce recall bias. Secondly, the prolonged data collection period of the UKB prevented us from distinguishing the effects of short-term versus long-term dietary iron intake on mental and behavioral disorders due to use of tobacco. Thirdly, the study was ultimately observational, preventing us from drawing causal conclusions. Lastly, although we had attempted to adjust for numerous confounding factors, the influence of unknown factors may persist.

5. CONCLUSION

In conclusion, we found a stable, protective effect of dietary iron intake against mental and behavioral disorders due to use of tobacco and a nonlinear relationship between dietary iron intake and mental and behavioral disorders due to use of tobacco. Our findings may provide valuable insights into how individuals can reduce mental and behavioral disorders due to use of tobacco by appropriately increasing dietary iron intake. Meanwhile, it offers reliable clues for future public health policy development.

Acknowledgments

We thank all the staff at the UKB. This research has been conducted using the UKB Resource under Application Number 95715

Contributors

XQ contributed to the conception, design, acquisition and interpretation of data, performed all statistical analyses and drafted and critically revised the manuscript. RZ, QZ, and JL contributed to the design, analysis and interpretation of results. TW and WW contributed to analysis and interpretation of results and critically revised the manuscript. HZ makes critical revisions to important intellectual content. DZ contributed to the conception, design and acquisition of data and critically revised the manuscript. All authors gave their final approval and agreed to be accountable for all aspects of the work.

Funding

Not applicable.

Competing interests

The authors declare no conflicts of interest.

Patient consent for publication

Not required.

Ethics approval

Ethical review for this study was obtained from the North West

Multi-Centre Research Ethics Committee in the UK (reference number:

11/NW/0382, 16/NW10274, 21/NW/0157).

Data availability statement

The data supporting the findings of this study are publicly available at

UK Biobank (<https://www.ukbiobank.ac.uk>).

References

1. Xiao D, Wang C Tobacco dependence should be recognised as a lethal non-communicable disease. *Bmj*. 2019;365:l2204. doi: 10.1136/bmj.l2204
2. Leiter A, Veluswamy RR, Wisnivesky JP The global burden of lung cancer: current status and future trends. *Nat Rev Clin Oncol*. 2023;20:624-39. doi: 10.1038/s41571-023-00798-3
3. Padrão E, Oliveira O, Felgueiras Ó, et al Tuberculosis and tobacco: is there any epidemiological association? *Eur Respir J*. 2018;51. doi: 10.1183/13993003.02121-2017
4. Chen J, Chen R, Xiang S, et al Cigarette smoking and schizophrenia: Mendelian randomisation study. *Br J Psychiatry*. 2021;218:98-103. doi: 10.1192/bjp.2020.116
5. Joachim GE, Bohnert KM, As-Sanie S, et al Cannabis smoking, tobacco cigarette smoking, and adenomyosis risk. *Fertil Steril*. 2023;119:838-46. doi: 10.1016/j.fertnstert.2023.01.035
6. Sargent JD, Halenar M, Steinberg AW, et al Childhood Cigarette Smoking and Risk of Chronic Obstructive Pulmonary Disease in Older U.S. Adults. *Am J Respir Crit Care Med*. 2023;208:428-34. doi: 10.1164/rccm.202303-0476OC
7. Organization WH. International Classification of Diseases, 10th edition (ICD-10) [online]. <https://icd.who.int/browse10/2019/en#> (accessed
8. Selby P, Zawertailo L Tobacco Addiction. *N Engl J Med*. 2022;387:345-54. doi: 10.1056/NEJMcp2032393
9. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet*. 2021;397:2337-60. doi: 10.1016/s0140-6736(21)01169-7

10. Prevention CfDca. National Health Interview Survey. 2017.
11. Prochaska JJ, Das S, Young-Wolff KC Smoking, Mental Illness, and Public Health. *Annu Rev Public Health*. 2017;38:165-85. doi: 10.1146/annurev-publhealth-031816-044618
12. Wittenberg RE, Wolfman SL, De Biasi M, et al Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction. *Neuropharmacology*. 2020;177:108256. doi: 10.1016/j.neuropharm.2020.108256
13. Mineur YS, Soares AR, Etherington IM, et al Pathophysiology of nAChRs: Limbic circuits and related disorders. *Pharmacol Res*. 2023;191:106745. doi: 10.1016/j.phrs.2023.106745
14. Torti SV, Manz DH, Paul BT, et al Iron and Cancer. *Annu Rev Nutr*. 2018;38:97-125. doi: 10.1146/annurev-nutr-082117-051732
15. Liang Y, Luo S, Wong THT, et al Association of iron homeostasis biomarkers in type 2 diabetes and glycaemic traits: a bidirectional two-sample Mendelian randomization study. *Int J Epidemiol*. 2023;52:1914-25. doi: 10.1093/ije/dyad093
16. Tan L, Zhou Q, Liu J, et al Association of iron status with non-alcoholic fatty liver disease and liver fibrosis in US adults: a cross-sectional study from NHANES 2017-2018. *Food Funct*. 2023;14:5653-62. doi: 10.1039/d2fo04082d
17. Xu J, Zhang S, Tian Y, et al Genetic Causal Association between Iron Status and Osteoarthritis: A Two-Sample Mendelian Randomization. *Nutrients*. 2022;14. doi: 10.3390/nu14183683
18. Qiu J, Lian F, Fang X Iron status and mental disorders: A Mendelian randomization study. *Front Nutr*. 2022;9:1084860. doi: 10.3389/fnut.2022.1084860
19. Hare D, Ayton S, Bush A, et al A delicate balance: Iron metabolism and diseases of the

brain. *Front Aging Neurosci.* 2013;5:34. doi: 10.3389/fnagi.2013.00034

20. Shah HE, Bhawnani N, Ethirajulu A, et al. Deficiency-Induced Changes in the Hippocampus, Corpus Striatum, and Monoamines Levels That Lead to Anxiety, Depression, Sleep Disorders, and Psychotic Disorders. *Cureus.* 2021;13:e18138. doi: 10.7759/cureus.18138

21. Li Z, Li B, Song X, et al. Dietary zinc and iron intake and risk of depression: A meta-analysis. *Psychiatry Res.* 2017;251:41-7. doi: 10.1016/j.psychres.2017.02.006

22. Yao S, Zhong Y, Xu Y, et al. Quantitative Susceptibility Mapping Reveals an Association between Brain Iron Load and Depression Severity. *Front Hum Neurosci.* 2017;11:442. doi: 10.3389/fnhum.2017.00442

23. Islam MR, Islam MR, Shalahuddin Qusar MMA, et al. Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: a case-control study. *BMC Psychiatry.* 2018;18:94. doi: 10.1186/s12888-018-1685-z

24. McGrath J, Brown A, St Clair DP. Prevention and schizophrenia--the role of dietary factors. *Schizophr Bull.* 2011;37:272-83. doi: 10.1093/schbul/sbq121

25. Galante J, Adamska L, Young A, et al. The acceptability of repeat Internet-based hybrid diet assessment of previous 24-h dietary intake: administration of the Oxford WebQ in UK Biobank. *British Journal of Nutrition.* 2016;115:681-6. doi: 10.1017/S0007114515004821

26. Liu B, Young H, Crowe FL, et al. Development and evaluation of the Oxford WebQ, a low-cost, web-based method for assessment of previous 24 h dietary intakes in large-scale prospective studies. *Public Health Nutrition.* 2011;14:1998-2005. doi: 10.1017/S1368980011000942

27. Perez-Cornago A, Pollard Z, Young H, et alDescription of the updated nutrition calculation of the Oxford WebQ questionnaire and comparison with the previous version among 207,144 participants in UK Biobank. *European Journal of Nutrition*. 2021;60:4019-30. doi: 10.1007/s00394-021-02558-4
28. Xiang AH, Martinez MP, Chow T, et alDepression and Anxiety Among US Children and Young Adults. *JAMA Netw Open*. 2024;7:e2436906. doi: 10.1001/jamanetworkopen.2024.36906
29. de Lima Queiroga L, Pitta RM, Ritti-Dias RM, et alPhysical activity levels are associated with depressive symptoms: A cross-sectional study of 58,445 adults. *J Affect Disord*. 2024. doi: 10.1016/j.jad.2024.09.158
30. Dakanalis A, Mentzelou M, Papadopoulou SK, et alThe Association of Emotional Eating with Overweight/Obesity, Depression, Anxiety/Stress, and Dietary Patterns: A Review of the Current Clinical Evidence. *Nutrients*. 2023;15. doi: 10.3390/nu15051173
31. Qi X, Jia Y, Pan C, et alIndex of multiple deprivation contributed to common psychiatric disorders: A systematic review and comprehensive analysis. *Neurosci Biobehav Rev*. 2022;140:104806. doi: 10.1016/j.neubiorev.2022.104806
32. Wang G, Sabran KAssessing depression and anxiety among young adults after epidemics and pandemics: a cross-sectional study in Anyang, China. *Sci Rep*. 2024;14:2759. doi: 10.1038/s41598-024-53292-w
33. Lee SK, Kwon YJSocioeconomic disparities in alcohol-related depression: a national cohort study of low-income medical aid beneficiaries and national health insurance beneficiaries in Korea. *BMC Public Health*. 2024;24:2189. doi: 10.1186/s12889-024-19665-6

34. Menzies V, Webb F, Lyon DE, et alAnxiety and depression among individuals with long COVID: Associations with social vulnerabilities. *J Affect Disord.* 2024;367:286-96. doi: 10.1016/j.jad.2024.08.214
35. Huang H, Meng F, Qi Y, et alAssociation of hypertension and depression with mortality: an exploratory study with interaction and mediation models. *BMC Public Health.* 2024;24:1068. doi: 10.1186/s12889-024-18548-0
36. Chieh A, Chu J, Wallace LA, et alDepression prevalence, screening, and treatment in adult outpatients with type 1 and type 2 diabetes: A nationally representative cross-sectional study (National Ambulatory Medical Care Survey 2014-2019). *J Affect Disord.* 2024;368:471-6. doi: 10.1016/j.jad.2024.09.088
37. Cassidy S, Chau JY, Catt M, et alCross-sectional study of diet, physical activity, television viewing and sleep duration in 233,110 adults from the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes. *BMJ Open.* 2016;6:e010038. doi: 10.1136/bmjopen-2015-010038
38. Liu S, Chen J, Guan L, et alThe brain, rapid eye movement sleep, and major depressive disorder: A multimodal neuroimaging study. *Prog Neuropsychopharmacol Biol Psychiatry.* 2024;136:111151. doi: 10.1016/j.pnpbp.2024.111151
39. Chen MH, Su TP, Chen YS, et alAssociation between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. *BMC Psychiatry.* 2013;13:161. doi: 10.1186/1471-244x-13-161
40. Stewart R, Hirani VRelationship Between Depressive Symptoms, Anemia, and Iron Status in Older Residents From a National Survey Population. 2012;74:208-13. doi:

10.1097/PSY.0b013e3182414f7d

41. Lee HS, Chao HH, Huang WT, et al Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. BMC Psychiatry. 2020;20:216. doi: 10.1186/s12888-020-02621-0

42. Beard JL, Erikson KM, Jones BC Neurobehavioral analysis of developmental iron deficiency in rats. Behav Brain Res. 2002;134:517-24. doi: 10.1016/s0166-4328(02)00092-x

43. Benowitz NL Nicotine addiction. N Engl J Med. 2010;362:2295-303. doi: 10.1056/NEJMra0809890

44. Bullen CE Electronic cigarettes for smoking cessation. Curr Cardiol Rep. 2014;16:538. doi: 10.1007/s11886-014-0538-8

45. Arastoo S, Haptonstall KP, Choroomi Y, et al Acute and chronic sympathomimetic effects of e-cigarette and tobacco cigarette smoking: role of nicotine and non-nicotine constituents. American journal of physiology Heart and circulatory physiology. 2020;319:H262-h70. doi: 10.1152/ajpheart.00192.2020

46. Republished: Nicotine and health. Bmj. 2014;349:2014.7.0264rep. doi: 10.1136/bmj.2014.7.0264rep

47. Martin-Soelch C Neuroadaptive changes associated with smoking: structural and functional neural changes in nicotine dependence. Brain Sci. 2013;3:159-76. doi: 10.3390/brainsci3010159

48. Burhans MS, Dailey C, Beard Z, et al Iron deficiency: differential effects on monoamine transporters. Nutr Neurosci. 2005;8:31-8. doi: 10.1080/10284150500047070

49. Youdim MB, Ben-Shachar D, Yehuda S Putative biological mechanisms of the effect of

iron deficiency on brain biochemistry and behavior. Am J Clin Nutr. 1989;50:607-15;

discussion 15-7. doi: 10.1093/ajcn/50.3.607

50. Daubner SC, Le T, Wang STyrosine hydroxylase and regulation of dopamine synthesis.

Arch Biochem Biophys. 2011;508:1-12. doi: 10.1016/j.abb.2010.12.017

51. Tekin I, Roskoski R, Jr., Carkaci-Salli N, et alComplex molecular regulation of tyrosine

hydroxylase. J Neural Transm (Vienna). 2014;121:1451-81. doi: 10.1007/s00702-014-1238-7